

Ref: EPL/CS/SE/0015/2024

Date: October 03, 2024

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Press Release

Please find enclosed herewith a Press Release titled "Emcure Pharmaceuticals Signs Agreement with Gilead for the Manufacture and Global Supply of Lenacapavir".

You are requested to take the same on your records.

Thanking you,

For Emcure Pharmaceuticals Limited



Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352



Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: U24231PN1981PLC024251

Press Release**Emcure Pharmaceuticals Signs Agreement with Gilead for the
Manufacture and Global Supply of Lenacapavir**

Pune, Oct 3, 2024: Emcure Pharmaceuticals, a leading Indian pharma company announces the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries.

Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.

Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals Ltd., said, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide."

Emcure's commitment to affordability and quality is backed by its expertise in manufacturing complex generic drugs. This partnership highlights Emcure's role as a leading manufacturer of generic pharma products and its commitment to innovative and affordable healthcare globally.

About Lenacapavir:

Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.

The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.

Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

About Gilead Sciences:

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.